The risk factors associated with hyperparasitemia at presentation and after treatment with different antimalarial drug regimens were evaluated in f ,048 children enrolled prospectively in seven antimalarial drug trials between July 1996 and September 2003 in a hyperendemic area of southwestern Nigeria. The outcomes of treatment of hyperparasitaemia, and gametocyte carriage following treatment were also evaluated. The children were assigned to one of seven treatment groups : chloroquine (CQ) only ; pyrimethamine-sulfadoxine (PS] only; amodiaquine (AQ) only; CQ plus chlorpheniramine (CQCP); PS combined with CQ or AQ (COM°); PS combined with probenecid (PPS); and halofantrine (HF|. Hyperparasitaemia was found in 100 (9,5 %] of the 1,048 children at enrolment (day 0). Following oral therapy, 1.2 % of all patients (i.e. 1 3 patients) became hypeparasitaemic, which developed in all patients by day 1 of follow-up. In a multiple regression model, age < 5 years, and a core temperature (oral or rectal) > 39.5°C were found to be independent risk factors for hyperparasitaemia at enrolment. Following therapy, the cure rate on day 1 4 was significantly lower in those treated with CQ compared to other treatment groups. Severe resistance (RIII) response to treatment occurred significantly more frequently in those with hyperparasitaemia at enrolment than in those without, and was seen in five and one child with hyperparasitaemia who were treated with CQ and CQCP, respectively. Gametocyte carriage was insignificantly lower at enrolment and at all times following treatment in children with hyperparasitaemia than in ageand gender-matched children without hyperparasitaemia who received the same treatment. The results are discussed in the light of management of uncomplicated hyperparasitaemia in children in endemic settings. 
The risk factors associated with hyperparasitemia at presentation and after treatment with different antimalarial drug regimens were evaluated in f ,048 children enrolled prospectively in seven antimalarial drug trials between July 1996 and September 2003 in a hyperendemic area of southwestern Nigeria. The outcomes of treatment of hyperparasitaemia, and gametocyte carriage following treatment were also evaluated. The children were assigned to one of seven treatment groups : chloroquine (CQ) only ; pyrimethamine-sulfadoxine (PS] only; amodiaquine (AQ) only; CQ plus chlorpheniramine (CQCP); PS combined with CQ or AQ (COM°); PS combined with probenecid (PPS); and halofantrine (HF|. Hyperparasitaemia was found in 100 (9,5 %] of the 1,048 children at enrolment (day 0). Following oral therapy, 1.2 % of all patients (i.e. 1 3 patients) became hypeparasitaemic, which developed in all patients by day 1 of follow-up. In a multiple regression model, age < 5 years, and a core temperature (oral or rectal) > 39.5°C were found to be independent risk factors for hyperparasitaemia at enrolment. Following therapy, the cure rate on day 1 4 was significantly lower in those treated with CQ compared to other treatment groups. Severe resistance (RIII) response to treatment occurred significantly more frequently in those with hyperparasitaemia at enrolment than in those without, and was seen in five and one child with hyperparasitaemia who were treated with CQ and CQCP, respectively. Gametocyte carriage was insignificantly lower at enrolment and at all times following treatment in children with hyperparasitaemia than in ageand gender-matched children without hyperparasitaemia who received the same treatment. The results are discussed in the light of management of uncomplicated hyperparasitaemia in children in endemic settings. uncomplicated hyperparasitaemia in children in these endemic areas be treated with oral antimalarial drugs providing the drug is rapidly absorbed and the para sites are fully sensitive to the antimalarial drug(s) chosen (Sowunmi et al, 1992 (Sowunmi et al, , 1996 (Sowunmi et al, , 2000 . Such a sugges tion needs review in view of the increasing resistance in P. falciparum to many antimalarials drugs and the lack of facilities to monitor drug sensitivity of P. falciparum in vitro and in vivo in many endemic areas. There is little information on, for example, the risk fac tors associated with uncomplicated hyperparasitaemia or the time-course of gametocytaemias following oral antimalarial treatment of uncomplicated hyperparasitaemias in African children. Such information is neces sary in view of the increasing resistance in P. falci parum to chloroquine (CQ) and other commonly available antimalarials and the increasing morbidity and mortality associated with drug resistance (Trape et al., 1998; Trape. 2001) . In addition, it may improve the overall management of these cases. The present study was designed to address these issues. The main aims of the study were : to evaluate the risk factors asso ciated with hyperparasitaemia in a group of children presenting with acute, symptomatic, apparently uncom plicated, P. falciparum malaria in an endemic area; to assess the outcomes of oral antimalarial treatment of uncomplicated hyperparasitaemia; and to follow the temporal changes in gametocytaemias in children with hyperparasitaemias who were treated with oral anti malarial drugs.
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PATIENTS AND METHODS
PATIENTS
T he study took place between July 1996 and September 2003 in patients presenting at the University College Hospital in Ibadan, a hyperendemic area for malaria in southwestern Nigeria (Salako et al., 1990) . Ethical clearance was provided by the local ethics committee. During the period, a series of antimalarial drug studies were conducted to evaluate the efficacy and safety-of different treatment regimens. All antimalarial drugs were given orally. The details of the studies have been described before (Sowunmi et al., 1998 (Sowunmi et al., a, b, c, 2000 Sowunmi. 2002 Sowunmi. , 2003 Sowunmi & Fateye, 2003) . Briefly, children with symptoms compatible with acute falciparum malaria who fulfilled the following criteria were enlisted in the study : age below 12 years, pure P. falciparum parasitaemia greater than 2000 asexual forms/uL blood, negative urine tests for antimalarial drugs (Dill-Glazko and lignin tests), absence of concomitant illness, no evidence of severe malaria (WHO, 2000 a) and written informed consent given by parents or guardians. After enrolment and start of treatment (day 0), follow-up with clinical and parasitological evaluation was at days 1-7, and then on days 14, and when necessary, on days 21 and 28, for example, in patients who received pyrimethamine-sulfadoxine ( ASSESSMENT OF PARASITAEMIA Thick and thin blood films prepared from a finger prick were Giemsa-stained and were examined by light microscopy under an oil-immersion objective, at x 1,000 magnification, by two independent assessors. Parasitaemia in thick films was estimated by counting asexual parasites relative to 1,000 leukocytes, or 500 asexual forms, whichever occurred first. From this figure, the parasite density was calculated assuming an average leukocyte count of 6,000, uL of blood (Shaper 6 Lewis, 1971; Ezeilo, 1971; Sowunmi et al., 1995) . Gametocytes were also counted in thick films against 1,000 leukocytes assuming an average leukocyte count of 6000/uL of blood at enrolment (day 0) and on days 7 and 14. Fractional gametocyte density (FGD) at enrolment was defined as gametocyte count divided by total asexual and sexual count (Price et al., 1999) . Haematocrit was done at enrolment in 124 of the patients treated with PS or CQPS, AQPS or PPS.
EVALUATION OF RESPONSE TO DRUG TREATMENT
Response to drug treatment was assessed using World Health Organization (WHO) criteria (WHO, 1973) as follows : S = sensitive, clearance of parasitaemia without recurrence; RI (mild resistance) = parasitaemia disappears but reappears within 7 to 14 days; RII (moderate resistance) = decrease of parasitaemia but no complete clearance from peripheral blood; RIII (severe resistance) = no pronounced decrease or increase in parasitaemia at 48 hours after treatment. In those with sensitive or RI response, parasite clearance time (PCT) was defined as the time elapsing from dnig administration until there was no patent parasitaemia for at least 72 h. Asexual parasite reduction ratio [PRR] (White, 1997) was defined as the ratio of day 0/day 2 parasitaemia.
RE-TREATMENT OF TREATMENT FAILURES
All patients with RII and RIII responses were re-treated with intramuscular artemether (9.6 mg/kg, over five days). Patients with RI response were re-treated with oral mefloquine 25 mg/kg single dose and followed 318 Mémoire Parasite. 2004. 11, 317-323 up for another M-28 clays. Patients were retreated whenever they became symptomatic or when they show profound clinical (hyperpyrexia, oral fluid into lerance) or parasitological deterioration.
STATISTICAL ANALYSIS
Data were analysed using version 6 of the Epi-Info soft ware (Anon., 1994) , and the statistical program SPSS for Windows version 10.01 (SPSS. 1999). Proportions were compared by calculating X 2 with Yates' correc tion or Fisher exact test. Normally distributed, conti nuous data were compared by Student's t-tests and analysis of variance (ANOVA). Data not conforming to a normal distribution were compared by the MannWhitney U-test and the Kruskal-Wallis test (or by Wilcoxon rank sum test). A multiple logistic regression model was used to test the association between hyperparasitaemia (yes or no at presentation or during follow up) and factors that were significant at univa riate analysis : age < 5 years, and presence of fever (oral or rectal temperature) > 39.5" C. Because the study was conducted over a period of seven years, time was included as a covariate in the analysis. P-values of < 0.05 were taken to indicate significant differences.
RESULTS
T
he demographic characteristics of the children enrolled in the study are summarized in Table I . At enrolment, 303. 173, 104, 203, 143, 78 and 44 of the 1,048 children w r ere allotted to, and were sub sequently treated with chloroquine (CQ) only; pyrimethamine-sulfadoxine (PS) only; amodiaquine (AQ) only; CQ plus chlorpheniramine (CQCP); PS com bined with CQ or AQ (COM); PS combined with pro benecid (PPS); and halofantrine (HF) [Halfan®, GlaxoSmithkline) . respectively. Hyperparasitaemia was found in 100 (9.5 %) of the 1.048 children at enrolment.
RISK FACTORS FOR HYPERPARASITAEMIA AT ENROLMENT
Factors associated with hyperparasitaemia at enrol ment are presented in Table II . Age < 5 years, and oral or rectal temperature > 39.5" C were independent risk factors for uncomplicated hyperparasitaemia at enrol ment. The clinical and parasitological characteristics of the 100 children who had hyperparasitaemia at enrolment and were treated with oral antimalarial drugs are sum marized in Table III . Despite enrolment at different per iods, these characteristics were similar (primarily because the criteria for enrolment into all studies were similar). No child with hyperparasitaemia was treated with AQ alone.
The responses of the asexual hyperparasitaemia to drug treatment are shown in PS, pyrimethamine-sulfadoxine; CQ, chloroquine; CQCP, chloroquine plus chlorpheniramine:
COM. pyrimethamine-sulfadoxine combined with chloroquine or amodiaquine;
PPS pyrimethamine-sulfadoxine combined with probenecid; HF. halofantrine.
* Excluded from multiple comparison because of relatively small number of patients.
** Parasitaemia at enrolment was 438.660 per uL. PRR. parasite reduction ratio: FCT. fever clearance time: PCT. parasite clearance time; PS. pyrimethamine-sulfadoxine: CQ. chloroquine; CQCP. chloroquine plus chlorpheniramine, COM. pyrimethamine-sulfadoxine combined with chloroquine or amodiaquine; PPS pyrimethamine-sulfadoxine combined with probenecid; HF. halofantrine; RI = parasitaemia disappears but reappears within 7 to 14 days; RII = decrease of parasitemia but no complete clearance from peripheral blood; RIII = no pronounced decrease or increase in parasitaemia at 48 hours after treatment. S = sensitive response. * Excluded from multiple comparison because of relatively small number of patients. Sixteen of 948 children without hyperparasitaemia had RIII response to treatment compared to six of 100 chil dren with hyperparasitaemia. The difference between these proportions was significant (% 2 = 6.22. P = 0.001). Four children (three treated with CQ and one with PS) aged < 3 years who had hyperparasitaemia progressed to cerebral malaria, while two of the 948 children without hyperparasitaemia had the same outcome. The difference between these two proportions was significant (P = 0.001. by Fisher exact test). The two children without hyperparasitaemia who progressed to cerebral malaria were treated with CQ. Adverse reac tions reported following drug treatment were similar in children with hyperparasitaemia and in age-and gender-matched children without hyperparasitaemia who were treated with the same drugs (data not shown). For example, in those treated with CQ, pru ritus occurred in five (of 33) and four (of 33) children with and without hyperparasitaemia. respectively.
GAMETOCYTE CARRIAGE AND GAMETOCYTAEMIA IN CHILDREN WITH HYPERPARASITAEMIA
In order to evaluate gametocyte carriage and gametocytaemia in those who were hyperparasitaemic at pre sentation, children with hyperparasitaemia were mat ched with those without hyperparasitaemia for time of presentation, age, gender, and drug treatment.
At enrolment gametocyte carriage was similar in chil dren with hyperparasitaemia and in age-and gendermatched children without hyperparasitaemia who received the same drug treatment (6 of 100 vs 11 of 100 children, X 1 = 1-03, P = 0.3). Similarly following treatment, gametocyte carriage was similar on day 7 (16 of 100 vs 27 of 100 children, x 2 = 2.9. P = 0.08) and on day 14 (9 of 100 vs 17 of 100 children, x 2 = 2.2, P = 0.14).
At enrolment gametocytaemia was similar in children with hyperparasitaemia and in age-and gender-mat ched children without hyperparasitaemia who received the same drug treatment (geometric mean 12, range 6-24/uL vs 14 range 6-72, P = 0.5). Similarly following treatment, gametocytaemia was similar on day 7 (geo metric mean 71. range 6-1320/uL vs 66, range 6-828, P = 0.4) and on day 14 (geometric mean 57, range 12-480 uL vs 70 range 12-360, P = 0.7). 
RE-TREATMENT OF TREATMENT FAILURES
All treatment failures responded to re-treatment with intramuscular artemether or oral mefloquine with clea rance of fever and parasitaemia within 72 h of com mencing re-treatment and with no recurrence of para sitaemia during additional 14-28 days of follow-up.
DISCUSSION
"Tncomplicated hyperparasitaemia is not uncommon in African children presenting with acute, symptomatic, falciparum malaria (Salako et al., 1990; Sowunmi el al., 1992 Sowunmi el al., , 1996 Sowunmi el al., , 2000 . Prevalence rates in endemic and non endemic areas in Africa probably vary widely; in southwest Nigeria, the rate is approximately 10-12 % (Sowunmi. unpublished data). The 10 % prevalence recorded in the present study was similar to that previously reported from the same area in the early 1990s (Salako et al.. 1990) . The risk factors associated with uncomplicated hyper parasitaemia at presentation are not frequently docu mented. In falciparum infections, younger age (< 3 years) has been associated with hyperparasi taemia and increased risk of progression to cerebral malaria (Sowunmi et al., 2000 a) . In the present study, age < 5 years and oral or rectal temperature > 39.5" C were independent risk factors associated with hyper parasitaemia at presentation. In falciparum infections in young children, the general trend is for parasi taemia to increase with time, and more specifically, to be accompanied by increases in body temperature. However, in severe infections there may be hypo thermia. In practice many children with lower oral or rectal temperatures than our model found may be hyperparasitaemic. This would be so becaLise many parents or guardians have ready access to over the counter remedies including antipyretics before pre sentation. This 'blunting' of presenting oral or rectal temperature may mislead the attending health care pro vider and distract attention from the possible presence of hyperparasitaemia. The responses of apparently uncomplicated hyperpa rasitaemia to oral therapy are less frequently reported, probably because of the dangers associated with oral therapy in a condition that may rapidly progress to a fatal outcome, and probably also because of increa sing resistance in P. falciparum to antimalarial drugs leading to reluctance to try oral therapy. Providing the parasites are fully sensitive to the oral drugs chosen, responses to drug therapy appears to be independent of parasite load. Thus in a comparative study, thera peutic responses of those with and without hyperpa rasitaemia were similar in children from an endemic area in West Africa (Sowunmi et al., 2000 a) . In addi tion, in drug sensitive infections, the disposition of parasitaemia appears to follow a first order kinetics (Sowunmi et al.. 2000 a. b ). In our cohort of children, CQ was the least effective drug in children with hyperparsitaemia and clearly represented a significant decline in the sensitivity of P. falciparum to this drug. Thus with prevailing degree of CQ resistance, this dnig may not be ideal for the treatment of malaria irrespective of parasite load. The significantly higher proportions of children without hyperparasitaemia who subse quently developed it following treatment with CQ or PS compared with the other treatment groups suggest slow onset of antimalarial action or reduced sensitivity to these drugs and a risk for development of post-treat ment hyperparasitaemia. Relatively low asexual parasitaemia and absence of fever are some of the risk factors associated with gametocyte carriage in falciparum infections (Price et al.. 1999; Akim et al., 2000; von Seidlein et al.. 2001) . The lower gametocyte carriage and gametocytaemia following treatment of the children with hyperparasi taemia indicate that oral therapy of this condition is not associated with undue generation of gametocytes. However, it is not known whether gametocytes arising from patients who had hyperparasitaemia are more infectious to the mosquito than those arising from patients without hyperparasitaemia who were treated with the same drugs.
Hyperparasitaemia is a potentially life threatening condi tion, and with or without other features of severe malaria requires close clinical and parasitological moni toring. Its occurrence in children from this endemic area without other overt features of severe falciparum malaria suggests the presence of some degree of immu nity, although these children are, in general, considered relatively non-immune compared with adults from the same endemic area, and are prone to multiple infec tions (Happi et al.. 2003) . Should oral CQ or PS conti nued to be used for a potentially life threatening situa tion in view of increasing resistance of P. falciparum to these drugs in Africa? We feel otherwise. A recent study suggests that AQ, a drug more effective than CQ in both CQ-sensitive and resistant-P. falciparum infec tions, rapidly clears hyperparasitaemia (Ndounga & Basco, 2003) . In the small number of children treated with a combination of PS plus AQ in our study popu lation, neither clearance nor parasite reduction ratio was significantly faster or higher, respectively than those of other treatments. In view of the fact that artemisinin and its derivatives clear parasitaemia more rapidly than most of the currently available antimalarials (Hien & White, 1993) , these drugs combined with, for example. AQ may be tried for the management of uncomplicated hyperparasitaemia in children from Africa. This sug gestion is predicated on the fact that AQ is a relatively safe daig (Olliaro et al., 1996) , and may be a suitable partner combination drug with the artemisinin deriva tives, for example, artesunate for use in Africa (Adjuik et al., 2002) . Studies to assess the efficacy of such com binations in uncomplicated and complicated hyperparasitaemias are under way in our study area.
